Shield Therapeutics plc (STX) Ordinary Shares 1.5p
0.75p
(1.22%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.75p
(1.22%)
0.75p
(1.22%)
61.25p
62.00p
72.50p
£72.18 million
61.25p
61.04p
15.10p
n/a
1.25p (2.00%) Previous:
1.25p
42,878
n/a
1,000
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2017 | 31/12/2016 |
|---|---|---|
| Revenue (£m) | 0.64 | 0.30 |
| Profit before tax (£m) | (20.99) | (15.60) |
| Adjusted EPS (p): | (15.00) | (9.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Open an easy to manage, low cost dealing account in less than 5 minutes
Deal shares from just £11.95 per trade online, and as low as £5.95 per trade for active traders.
More about the Fund and Share AccountImportant Documents
There are no documents available for this stock.
Broker forecasts
-
Strong Sell
(0 of 2) -
Sell
(0 of 2) -
Neutral
(0 of 2) -
Buy
(0 of 2) -
Strong Buy
(2 of 2)
This is not a recommendation, it represents the consensus view of a basket of brokers. If fewer than 5 brokers it may not be a valid consensus. HL might not concur and takes no responsibility.
Full broker forecasts-
Shield Therapeutics upbeat on latest Feraccru trial results
4 March 2019 11:26
-
Shield Therapeutics upbeat on results of latest Feraccru study
29 January 2019 10:02
-
Shield Therapeutics revenues surge following commercialisation deal
24 January 2019 10:02
-
Positive decision on Feraccru®'s process patent
14 March 2019 15:31
-
Positive results for Feraccru® in AEGIS-H2H study
4 March 2019 07:00
-
Positive results of AEGIS-CKD study
29 January 2019 07:00
| Time / date Time | Buy / sell Type | Volume | Price | Value |
|---|
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled ‘N/A’.
Annual & interim reports
Annual & interim reports are not available for this stock.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.